Pall (PLL $43.95 -4.87) reported fourth quarter pro forma EPS of $0.76 versus the $0.88 consensus.
Revenues rose 15% y/y to $780.4 million versus the $759.4 million consensus.
"Against a backdrop of global macroeconomic challenges, sales in both businesses met our expectations. Life Sciences' overall performance was solid while profitability in Pall Industrial fell short of what we anticipated. The end result is that the fourth quarter is a disappointing finish to an otherwise good year."






